|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
82,110,000 |
Market
Cap: |
3.30(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$31.73 - $53.69 |
|
Level
I Sector: |
Consumer Discretionary |
Level
II Sector: |
Leisure |
Level
III Sector: |
Restaurants |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ COMPOSITE |
|
NASDAQ INDUSTRIAL |
|
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
24,200 |
99,487 |
198,726 |
249,694 |
Total Sell Value |
$1,216,805 |
$4,824,734 |
$8,206,765 |
$10,494,293 |
Total People Sold |
3 |
8 |
9 |
12 |
Total Sell Transactions |
4 |
12 |
20 |
35 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Crombez Eric |
EVP and Chief Medical Officer |
|
2024-05-02 |
4 |
S |
$43.66 |
$15,456 |
D/D |
(354) |
48,431 |
|
11% |
|
Crombez Eric |
EVP and Chief Medical Officer |
|
2024-04-18 |
4 |
S |
$44.10 |
$6,262 |
D/D |
(142) |
48,785 |
|
11% |
|
Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
|
2024-04-16 |
4 |
D |
$42.31 |
$592 |
D/D |
(14) |
41,366 |
|
- |
|
Kassberg Thomas Richard |
CBO & EVP |
|
2024-03-11 |
4 |
S |
$49.93 |
$574,644 |
D/D |
(11,509) |
252,823 |
|
20% |
|
Fust Matthew K |
|
|
2024-03-07 |
4 |
S |
$50.85 |
$620,443 |
D/D |
(12,195) |
14,860 |
|
24% |
|
Crombez Eric |
EVP and Chief Medical Officer |
|
2024-03-01 |
4 |
S |
$53.76 |
$66,555 |
D/D |
(1,238) |
48,927 |
|
28% |
|
Crombez Eric |
EVP and Chief Medical Officer |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
19,400 |
49,912 |
|
- |
|
Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
|
2024-03-01 |
4 |
S |
$53.76 |
$18,332 |
D/D |
(341) |
41,380 |
|
28% |
|
Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
|
2024-03-01 |
4 |
D |
$53.69 |
$6,496 |
D/D |
(121) |
41,721 |
|
- |
|
Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,950 |
41,842 |
|
- |
|
Parschauer Karah Herdman |
EVP and Chief Legal Officer |
|
2024-03-01 |
4 |
S |
$53.76 |
$201,923 |
D/D |
(3,756) |
67,340 |
|
28% |
|
Parschauer Karah Herdman |
EVP and Chief Legal Officer |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
18,757 |
70,739 |
|
- |
|
Huang Dennis Karl |
See Remarks |
|
2024-03-01 |
4 |
D |
$53.69 |
$25,234 |
D/D |
(470) |
83,002 |
|
- |
|
Huang Dennis Karl |
See Remarks |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
18,757 |
83,472 |
|
- |
|
Horn Howard |
Chief Financial Officer |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
19,400 |
99,766 |
|
- |
|
Kakkis Emil D |
President & CEO |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
41,560 |
563,913 |
|
- |
|
Kakkis Emil D |
President & CEO |
|
2024-03-01 |
4 |
D |
$53.69 |
$935,119 |
D/D |
(17,417) |
560,781 |
|
- |
|
Pinion John Richard |
See Remarks |
|
2024-03-01 |
4 |
S |
$53.76 |
$224,340 |
D/D |
(4,173) |
89,268 |
|
28% |
|
Pinion John Richard |
See Remarks |
|
2024-03-01 |
4 |
D |
$53.69 |
$3,221 |
D/D |
(60) |
93,441 |
|
- |
|
Pinion John Richard |
See Remarks |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
18,757 |
93,501 |
|
- |
|
Harris Erik |
EVP & Chief Commercial Officer |
|
2024-03-01 |
4 |
S |
$53.76 |
$256,328 |
D/D |
(4,768) |
67,163 |
|
28% |
|
Harris Erik |
EVP & Chief Commercial Officer |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
20,357 |
71,638 |
|
- |
|
Kassberg Thomas Richard |
CBO & EVP |
|
2024-03-01 |
4 |
S |
$53.76 |
$54,351 |
D/D |
(1,011) |
264,332 |
|
28% |
|
Kassberg Thomas Richard |
CBO & EVP |
|
2024-03-01 |
4 |
D |
$53.69 |
$14,711 |
D/D |
(274) |
265,343 |
|
- |
|
Kassberg Thomas Richard |
CBO & EVP |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
18,757 |
265,617 |
|
- |
|
628 Records found
|
|
Page 1 of 26 |
|
|